Dos Santos, Rafael Guimarães http://orcid.org/0000-0003-2388-4745
de Lima Osório, Flávia http://orcid.org/0000-0003-1396-555X
Martin-Santos, Rocio http://orcid.org/0000-0003-4150-4726
Zuardi, Antonio Waldo http://orcid.org/0000-0002-0479-6670
Hallak, Jaime Eduardo Cecilio http://orcid.org/0000-0002-8784-0189
Crippa, José Alexandre S. http://orcid.org/0000-0001-9520-6746
Funding for this research was provided by:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Article History
First Online: 15 October 2019
Compliance with Ethical Standards
:
: RGS is a Fellow of the Brazilian National Post-Doctorate Program (PNPD/CAPES). FdLO has received support from the São Paulo Research Foundation (FAPESP). RMS has received support from the Generalitat de Catalunya (Spain) (SGR2017/1798). JASC and JECH received a CNPq (Brazil) Productivity Fellowship Award. None of the authors received any specific funding for writing this article.
: JASC and JECH have received travel support from and were medical advisors of SCBD Centre. JASC has received a grant from the University Global Partnership Network (UGPN)—“Global priorities in cannabinoid research excellence.” JASC is a member of the international advisory board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), funded by the National Health and Medical Research Council through the Centre of Research Excellence. JASC and JECH are co-inventors (Mechoulam R, Crippa JA, Guimaraes FS, Zuardi A, Hallak JE, and Breuer A) of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023” Def. US no. Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927). Universidade de São Paulo has licensed the patent to Phytecs Pharm (USP Resolution no. 15.1.130002.1.1). The University of São Paulo (USP) has an agreement with Prati-Donaduzzi (Toledo, Brazil) to “develop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” RGS, FdLO, RMS and AWZ report no conflicts of interest.